Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Scinai Immunotherapeutics Ltd. American Depositary Shares

SCNI

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.

Last trade $0.3999
Day change -$0.0042 (-1.04%)
Day range $0.354 – $0.412
Volume 38,423
Market cap $1M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SCNI.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for SCNI.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

Scinai Immunotherapeutics will lead a roundtable discussion at the 7th Dermatology Drug Development Summit Europe in Amsterdam, exploring how oral peptide and small molecule therapies may complement, compete with, or displace injectable biologic therapies in immunology and dermatology. The discussion will address key challenges including pharmacokinetic variability, bioavailability, treatment adherence, and the evolving balance between efficacy and convenience in immunotherapy development.

Benzinga

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Scinai Immunotherapeutics (NASDAQ: SCNI) received a Nasdaq notification on March 12, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share, as its closing bid price fell below this threshold for 30 consecutive business days. The company has been given 180 calendar days (until September 8, 2026) to regain compliance. If the stock closes at or above $1.00 for ten consecutive business days during this period, Nasdaq will confirm compliance and close the matter.

Benzinga

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Scinai Immunotherapeutics has regained full compliance with Nasdaq's listing requirements after converting $29 million of debt into equity, leaving a debt balance of $273,000. This clears the path for the company to focus on its R&D programs and CDMO business unit.

GlobeNewswire Inc.

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced receipt of a letter from the Nasdaq Stock Market ("Nasdaq") dated November 1, 2023, regarding non-compliance with the requirement to maintain a minimum bid price of $1.00 per share.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 19, 20261-for-4reverse split
Aug 21, 20261-for-10reverse split
May 21, 20241-for-10reverse split
Nov 25, 20221-for-10reverse split